Briefly Bio, a biotech startup simplifying complex lab processes, has launched with $1.2 million in pre-seed funding.
Co-founded in 2022 by Dr. Harry Rickerby, Dr Katya Putintseva, and Staffan Piledahl, the company has launched innovative software to make lab work easily reproducible by allowing scientists to capture their work clearly and share it consistently.
According to the company’s announcement reported by Health Tech Digital, the pre-seed round was spearheaded by Compound VC, with a significant contribution from Tiny VC, NP Hard, and multiple angel investors from the biotechnology and technology sectors.
A Step in the Right Direction
Biological experiments are complex, requiring more time and resources. However, critical details of shared understanding are often lost due to a lack of proper documentation.
Even so, efforts to make experiments reproducible have resulted in over 50% failure rate, costing the industry some $50 billion annually.
The lack of proper mechanisms for reproducing experiments makes scientific collaborations very inefficient. As a result, scientists struggle to reproduce experiments and build on other existing ones, leaving data scientists without the necessary benchmark data to analyze their own.
Additionally, the lack of proper experiment documentation and sharing techniques leaves automation teams without crucial details to build robotic labs. These are some of the existing problems in lab research that Briefly Bio is looking to solve with its innovative technology.
Briefly Bio’s software is designed to help lab scientists create a common language that fosters understanding among themselves and allows any project collaborator to understand.
Briefly Bio’s AI-powered software converts the metadata for the existing experiment into the new easy-to-understand format, spotting errors and automatically filling the gaps. The software creates a new standard way of storing experiment details and sharing them with those needing them.